Centuple Global Ltd (CHECKPOINT) — shareholding pattern, promoter holding, financials and share price
About Centuple Global Ltd (CHECKPOINT)
Centuple Global Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CHECKPOINT and on the BSE under scrip code 531099. Its ISIN is INE396H01019.
Incorporated in 1991, Checkpoint Trends Ltd is in the business of trading and consultancy [1]
Checkpoint Trends Limited, previously known as Rubra Medicaments Ltd, was established in 1991 and is now involved in trading and consultancy services.
The company has transitioned from manufacturing pharmaceutical formulations to offering a broad array of consulting services across various sectors.
Listed peers in Pharmaceuticals: Venmax Drugs & Pharmaceuticals Ltd, Ishita Drugs & Industries Ltd, Cian Healthcare Ltd, Rekvina Labs Ltd, Mono Pharmacare Ltd, Desh Rakshak Aushdhalaya Ltd.
Valuation & Returns
10 Jul 2026At ₹39.98 a share on 10 Jul 2026, Centuple Global Ltd (CHECKPOINT) was valued at a price-to-earnings ratio of 14.57x against an industry P/E of 36.41x and a price-to-book of 39.17x on a book value of ₹1.02 per share as of Mar 2025. Solomo computes return on equity of 268.72% and return on capital employed of 410.25% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 14.57x
- Industry P/E
- 36.41x
- P/B
- 39.17x
- EPS (TTM)
- ₹2.74
- Book value / share
- ₹1.02
- ROE
- 268.72%
- ROCE
- 410.25%
- ROA
- 229.89%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 0.4%
- 52-week range
- ₹28.22 – ₹144.4
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Centuple Global Ltd (CHECKPOINT) reported revenue of ₹574 crore, net profit of ₹2 crore and earnings per share of ₹2.76. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹279.41 crore and net profit ₹-0.48 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 2 | 1 | 1 | 0 | 574 |
| Net profit (₹ cr) | 0 | 0 | 0 | 0 | 2 |
| EPS (₹) | -0.07 | -0.15 | 0.05 | 0.05 | 2.76 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 11.01% | -12.73% | -37.12% | -55.75% |
| Profit growth | - | -4.25% | - | - |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 0% of Centuple Global Ltd (CHECKPOINT) (unchanged from the previous quarter), foreign institutional investors (FII) hold 8.59%. Market capitalisation was ₹22 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Mar 2026: RELIGARE FINVEST LTD 5.89%, M7 GLOBAL FUND PCC - CELL DEWCAP FUND 5.48%, AMAY VATSALYA 4.26%, GOLDEN BIO ENERGY LIMITED 3.87%, RAKESH BAID 3.66%, GATRAJ JAIN 3.66%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 0% | - | 8.59% | - | 100% |
| Dec 2025 | 0% | - | 10.71% | - | 100% |
| Sep 2025 | 0% | - | 10.86% | - | 100% |
| Jun 2025 | 0% | - | 10.86% | - | 100% |
| Mar 2025 | 0% | - | 10.85% | - | 100% |
| Dec 2024 | 0% | - | - | - | 100% |
| Sep 2024 | 0% | - | - | - | 100% |
| Jun 2024 | 0% | - | - | - | 100% |